Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05877222 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants
A Phase 1 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05877222 is a Phase 1 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT05877222, a Phase 1 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
A Phase 1 trial to investigate bioequivalence between 5 × 10 mg tablets and 2 × 25 mg tablets of daridorexant in healthy male and female Japanese participants
Interventions
- DRUG Daridorexant 25 mg
- DRUG Daridorexant 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-06-23 |
| Est. Completion | 2023-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05877222
The ClinicalTrials.gov registry entry for NCT05877222 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Daridorexant 25 mg is the first listed.
NCT05877222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05877222 about?
NCT05877222 is a clinical study titled "A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants". A Phase 1 trial to investigate bioequivalence between 5 × 10 mg tablets and 2 × 25 mg tablets of daridorexant in healthy male and female Japanese participants
What is the current status of trial NCT05877222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2023-06-23. Estimated completion is 2023-08-04.
What interventions are being tested in trial NCT05877222?
The interventions under investigation include: Daridorexant 25 mg (DRUG), Daridorexant 10 mg (DRUG).
Who is sponsoring clinical trial NCT05877222?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.